Standard Biotools (LAB) Cost of Revenue (2010 - 2026)

Standard Biotools (LAB) has 17 years of Cost of Revenue data on file, last reported at $9.8 million in Q1 2026.

• On a quarterly basis, Cost of Revenue rose 7.25% year-over-year to $9.8 million in Q1 2026; TTM through Mar 2026 was $43.5 million, a 2.73% decrease from a year earlier, with the FY2025 full-year figure at $42.8 million, down 7.23% from the prior year.
• Cost of Revenue for Q1 2026 stood at $9.8 million, down from $12.4 million in the prior quarter.
• Over the last five years, Cost of Revenue for LAB reached as high as $21.4 million in Q1 2024 and fell as low as $1.9 million in Q1 2022.
• Historically, Cost of Revenue has averaged $12.6 million across 5 years, with a median of $12.8 million in 2023.
• Across the five-year window, Cost of Revenue slumped 83.47% in 2022 and soared 565.87% in 2023, its largest moves.
• Year by year, Cost of Revenue stood at $15.9 million in 2022, then dropped by 6.45% to $14.8 million in 2023, then decreased by 9.51% to $13.4 million in 2024, then dropped by 7.5% to $12.4 million in 2025, then fell by 20.74% to $9.8 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $9.8 million in Q1 2026, $12.4 million in Q4 2025, and $10.1 million in Q3 2025.